Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Signs of dehydration
4 Placebo-adjusted weight reduction is even greater for patients without diabetes: 12.4% for semaglutide and 17.8% for tirzepatide
Obtaining insurance coverage is often fraught with difficulties as many insurers reject claims for these drugs, thus exacerbating financial hurdles and potentially preventing patients from getting these transformative therapies
The SURMOUNT trial program provides extensive data on what tirzepatide achieves without any additional weight loss medication: 5 mg dose: 15.0% average weight loss at 72 weeks 10 mg dose: 19.5% average weight loss at 72 weeks 15 mg dose: 20.9% average weight loss at 72 weeks At 15 mg, 56.1% of participants lost at least 20% of body weight At 15 mg, 38.7% of participants lost at least 25% of body weight These numbers are remarkable
